X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Dr. Reddy’s: The generic effect - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Jan 9, 2002

    Dr. Reddy’s: The generic effect

    Dr. Reddy’s is expected to report another spectacular quarterly performance for 3QFY02. While sales (incl. milestone receipts) is expected to record a jump of more than 85%, net profit is likely to explode with a 331% rise. Operating margins are likely to record a quantum jump, mainly due to a larger contribution from high margin generic exports.

    The spurt in export margins is expected on the back of exports of generic fluoxetine to the US markets. It may be recalled that Dr. Reddy’s received six month marketing exclusivity for this drug (Para IV) in August’01. The company had recorded sales of Rs 1,639 m in the last quarter from sales of fluoxetine with very high operating margins. We expect fluoxetine sales to record revenues of around Rs 950 m in 3QFY02 due to earlier stock build up.

    Dr. Reddy’s: High Voltage Performance
    (Rs m) 3QFY01 3QFY02E % change
    Sales 2,144 3,977 85.5%
    Operating Profit (EBDIT) 457 1,556 240.9%
    Operating Profit Margin (%) 21.3% 39.1%  
    Profit after Tax/(Loss) 320 1,377 331.0%
    Net profit margin (%) 14.9% 34.6%  
    Fully Diluted Earnings per share* 17.3 74.4  

    Dr. Reddy’s is also expected to receive a milestone payment of US $ 2.5 m from Novo Nordisk. This milestone receipt has been triggered by DRF- 2725 entering Phase III in Nov’01. Excluding sales of fluoxetine and receipt of milestone payments, sales growth is expected to be 36%. This is also because of the merger effect with American remedies.

    At the current market price of Rs 970, the stock trades at a P/e of 15x its expected earnings for FY02. However, one should also keep in mind that supernormal profits are expected to vanish from 4QFY02, as the company loses marketing exclusivity over fluoxetine. The spurt in operating margins was mainly because a six-month Para IV approval ensures high profit margins, due to absence of generic competition. Next Para IV application for the company is atleast 24 months away.

    Armed with huge cash reserves, an acquisition of a marketing company in the US may be in the offing. On the R&D front, DRF – 2725, the anti-diabetes molecule licensed to Novo Nordisk is at advanced trial stage before entering the commercialization stage. This could trigger huge royalty for the company (though disappointment on this front even at this stage cannot be ruled out.)

    Comparative Valuation
    Particulars CMP P/e Mkt.Cap
      (Rs.) 2002E 2003E (In Mn.)
    Ranbaxy 726 24.4 24.5 84,143
    Cipla 1180 28.4 22.1 70,800
    Dr.Reddy's 970 14.5 24.7 74,108

     

     

    Equitymaster requests your view! Post a comment on "Dr. Reddy’s: The generic effect ". Click here!

      
     

    More Views on News

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

    Sep 12, 2016

    Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    DR. REDDYS LAB SHARE PRICE


    Aug 18, 2017 (Close)

    TRACK DR. REDDYS LAB

    • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    DR. REDDYS LAB 5-YR ANALYSIS

    Detailed Financial Information With Charts

    COMPARE DR. REDDYS LAB WITH

    MARKET STATS